![Virtual Booth](https://www.pharmacompass.com/image/vb/vb-orange-btn.png)
![Renejix CDMO Partner for Small Molecule Oral Dosage Forms](https://www.pharmacompass.com/image/flap/renejix-w35-desktop-header-01gif-33629.gif)
![Renejix CDMO Partner for Small Molecule Oral Dosage Forms](https://www.pharmacompass.com/image/flap/renejix-w35-mob-header-01gif-17728.gif)
X
20
Calao S.r.l. Milano It, based in U.S.A, is a pharmaceutical company.
One of their significant offerings is Buflomedil Hydrochloride, supported by a 'Withdrawn by Holder' Certificate of Suitability (CEP) with the number R1-CEP 2000-131 - Rev 04
This Chemical Type CEP, issued on February 24, 2011, remains in force until December 16, 2011, ensuring its reliability within the pharmaceutical industry.
Substance Number 1398 associated with this CEP further emphasizes